BOCA RATON, Fla. & SARASOTA, Fla.--(BUSINESS WIRE)--Akron Bio (“Akron”), a provider of critical inputs for cell and gene therapies, today announced the appointment of Christopher Murphy as Chief Executive Officer. Akron is a portfolio company of Arcline Investment Management.
Mr. Murphy is a biotechnology industry veteran with more than 30 years of experience in advanced therapy and biological drug development and manufacturing. Most recently, he served as Vice President and General Manager of Viral Vector Services at Thermo Fisher Scientific. Mr. Murphy joined Thermo Fisher Scientific as part of its acquisition of Brammer Bio, where he served as Chief Operations Officer. Previously, he held leadership roles at Sanofi Genzyme, BioReliance, and Lederle Laboratories (now Pfizer).
Arcline commented, “Chris brings an exceptional track record of building and growing businesses that address critical demands in the rapidly developing cell and gene therapy industry. We are thrilled to welcome Chris as Akron’s CEO and believe his passion and expertise will be invaluable in strengthening the company’s position as a leading supplier to cell and gene therapy companies.”
Mr. Murphy said, “I am incredibly excited to join Akron Bio and partner with innovators to provide high-quality, critical materials and services that power the future of medicine. Our differentiated products, expertise, and agility are crucial in this rapidly evolving advanced therapy industry. I look forward to working with this exceptional team to enable customers to realize the potential of these medicines for people in need.”
About Akron Bio
Akron Bio is a leading materials manufacturer and services provider to the regenerative medicine industry. Akron Bio leverages more than 100,000 square feet of development and manufacturing capacity to provide advanced therapy developers the scale, compliance and regulatory support necessary to drive novel treatments from discovery to commercialization. For more information, please visit www.akronbiotech.com.
